{
  "symbol": "AMGN",
  "year": 2022,
  "Period": "Y2022",
  "report_type": "K10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1927,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.188
  },
  "top_positive": [
    {
      "sent": "(a) (b) (c) Plan category Number of securities to be issued upon exercise of outstanding options and rights Weighted-average exercise price of outstanding options and rights Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) Equity compensation plans approved by Amgen security holders: Amended and Restated 2009 Equity Incentive Plan (1) 10,217,143 $ 197.27 18,987,053 Amended and Restated 1991 Equity Incentive Plan (2) 3,550 \u2014 \u2014 Amended and Restated Employee Stock Purchase Plan \u2014 \u2014 4,280,585 Total approved plans 10,220,693 197.27 23,267,638 Equity compensation plan not approved by Amgen security holders: Amgen Profit Sharing Plan for Employees in Ireland (3) \u2014 \u2014 242,172 Total unapproved plans \u2014 \u2014 242,172 Total all plans 10,220,693 $ 197.27 23,509,810 (1) The Amended and Restated 2009 Equity Incentive Plan employs a fungible share-counting formula for determining the number of shares available for issuance under the plan.",
      "score": 0.9896
    },
    {
      "sent": "(a) (b) (c) Plan category Number of securities to be issued upon exercise of outstanding options and rights Weighted-average exercise price of outstanding options and rights Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) Equity compensation plans approved by Amgen security holders: Amended and Restated 2009 Equity Incentive Plan (1) 10,217,143 $ 197.27 18,987,053 Amended and Restated 1991 Equity Incentive Plan (2) 3,550 \u2014 \u2014 Amended and Restated Employee Stock Purchase Plan \u2014 \u2014 4,280,585 Total approved plans 10,220,693 197.27 23,267,638 Equity compensation plan not approved by Amgen security holders: Amgen Profit Sharing Plan for Employees in Ireland (3) \u2014 \u2014 242,172 Total unapproved plans \u2014 \u2014 242,172 Total all plans 10,220,693 $ 197.27 23,509,810 (1) The Amended and Restated 2009 Equity Incentive Plan employs a fungible share-counting formula for determining the number of shares available for issuance under the plan.",
      "score": 0.9896
    },
    {
      "sent": "(a) (b) (c) Plan category Number of securities to be issued upon exercise of outstanding options and rights Weighted-average exercise price of outstanding options and rights Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) Equity compensation plans approved by Amgen security holders: Amended and Restated 2009 Equity Incentive Plan (1) 10,217,143 $ 197.27 18,987,053 Amended and Restated 1991 Equity Incentive Plan (2) 3,550 \u2014 \u2014 Amended and Restated Employee Stock Purchase Plan \u2014 \u2014 4,280,585 Total approved plans 10,220,693 197.27 23,267,638 Equity compensation plan not approved by Amgen security holders: Amgen Profit Sharing Plan for Employees in Ireland (3) \u2014 \u2014 242,172 Total unapproved plans \u2014 \u2014 242,172 Total all plans 10,220,693 $ 197.27 23,509,810 (1) The Amended and Restated 2009 Equity Incentive Plan employs a fungible share-counting formula for determining the number of shares available for issuance under the plan.",
      "score": 0.9896
    }
  ],
  "top_negative": [
    {
      "sent": "16 Molecule Investigational indication Phase 3 programs AMJEVITA Interchangeability Bemarituzumab GEJ adenocarcinoma BLINCYTO Ph-negative B-cell precursor Acute lymphoblastic leukemia EVENITY Male osteoporosis KYPROLIS Weekly dosing for relapsed multiple myeloma Nplate Chemotherapy-induced thrombocytopenia Otezla Genital psoriasis Repatha Cardiovascular disease TEZSPIRE Chronic rhinosinusitis with nasal polyps Severe asthma ABP 654 Investigational biosimilar to STELARA (ustekinumab) ABP 938 Investigational biosimilar to EYLEA (aflibercept) ABP 959 Investigational biosimilar to SOLIRIS (eculizumab) Phase 2 programs Efavaleukin alfa Systemic lupus erythematosus Ulcerative colitis LUMAKRAS/LUMYKRAS Advanced colorectal cancer NSCLC monotherapy Other solid tumors with KRAS G12C mutations Olpasiran Cardiovascular disease Ordesekimab Celiac disease Otezla Palmoplantar pustulosis Rozibafusp alfa Systemic lupus erythematosus Tarlatamab Small cell lung cancer TEZSPIRE Chronic obstructive pulmonary disease Chronic spontaneous urticaria AMG 451/KHK 4083 Atopic dermatitis Phase 1 programs Acapatamab Prostate cancer Pavurutamab Multiple myeloma Tarlatamab Small-cell lung cancer AMG 104 Asthma AMG 119 Small-cell lung cancer AMG 133 Obesity AMG 176 Hematologic malignancies AMG 193 Solid tumors AMG 199 Metastatic GEJ cancer AMG 256 Solid tumors AMG 330 Acute myeloid leukemia AMG 340 Prostate cancer AMG 404 Solid tumors AMG 427 Acute myeloid leukemia AMG 506 Solid tumors AMG 509 Prostate cancer AMG 609 Nonalcoholic steatohepatitis AMG 650 Solid tumors AMG 994 Solid tumors 17 Phase\u00a03 Clinical trials investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study.",
      "score": -0.9842
    },
    {
      "sent": "16 Molecule Investigational indication Phase 3 programs AMJEVITA Interchangeability Bemarituzumab GEJ adenocarcinoma BLINCYTO Ph-negative B-cell precursor Acute lymphoblastic leukemia EVENITY Male osteoporosis KYPROLIS Weekly dosing for relapsed multiple myeloma Nplate Chemotherapy-induced thrombocytopenia Otezla Genital psoriasis Repatha Cardiovascular disease TEZSPIRE Chronic rhinosinusitis with nasal polyps Severe asthma ABP 654 Investigational biosimilar to STELARA (ustekinumab) ABP 938 Investigational biosimilar to EYLEA (aflibercept) ABP 959 Investigational biosimilar to SOLIRIS (eculizumab) Phase 2 programs Efavaleukin alfa Systemic lupus erythematosus Ulcerative colitis LUMAKRAS/LUMYKRAS Advanced colorectal cancer NSCLC monotherapy Other solid tumors with KRAS G12C mutations Olpasiran Cardiovascular disease Ordesekimab Celiac disease Otezla Palmoplantar pustulosis Rozibafusp alfa Systemic lupus erythematosus Tarlatamab Small cell lung cancer TEZSPIRE Chronic obstructive pulmonary disease Chronic spontaneous urticaria AMG 451/KHK 4083 Atopic dermatitis Phase 1 programs Acapatamab Prostate cancer Pavurutamab Multiple myeloma Tarlatamab Small-cell lung cancer AMG 104 Asthma AMG 119 Small-cell lung cancer AMG 133 Obesity AMG 176 Hematologic malignancies AMG 193 Solid tumors AMG 199 Metastatic GEJ cancer AMG 256 Solid tumors AMG 330 Acute myeloid leukemia AMG 340 Prostate cancer AMG 404 Solid tumors AMG 427 Acute myeloid leukemia AMG 506 Solid tumors AMG 509 Prostate cancer AMG 609 Nonalcoholic steatohepatitis AMG 650 Solid tumors AMG 994 Solid tumors 17 Phase\u00a03 Clinical trials investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study.",
      "score": -0.9842
    },
    {
      "sent": "16 Molecule Investigational indication Phase 3 programs AMJEVITA Interchangeability Bemarituzumab GEJ adenocarcinoma BLINCYTO Ph-negative B-cell precursor Acute lymphoblastic leukemia EVENITY Male osteoporosis KYPROLIS Weekly dosing for relapsed multiple myeloma Nplate Chemotherapy-induced thrombocytopenia Otezla Genital psoriasis Repatha Cardiovascular disease TEZSPIRE Chronic rhinosinusitis with nasal polyps Severe asthma ABP 654 Investigational biosimilar to STELARA (ustekinumab) ABP 938 Investigational biosimilar to EYLEA (aflibercept) ABP 959 Investigational biosimilar to SOLIRIS (eculizumab) Phase 2 programs Efavaleukin alfa Systemic lupus erythematosus Ulcerative colitis LUMAKRAS/LUMYKRAS Advanced colorectal cancer NSCLC monotherapy Other solid tumors with KRAS G12C mutations Olpasiran Cardiovascular disease Ordesekimab Celiac disease Otezla Palmoplantar pustulosis Rozibafusp alfa Systemic lupus erythematosus Tarlatamab Small cell lung cancer TEZSPIRE Chronic obstructive pulmonary disease Chronic spontaneous urticaria AMG 451/KHK 4083 Atopic dermatitis Phase 1 programs Acapatamab Prostate cancer Pavurutamab Multiple myeloma Tarlatamab Small-cell lung cancer AMG 104 Asthma AMG 119 Small-cell lung cancer AMG 133 Obesity AMG 176 Hematologic malignancies AMG 193 Solid tumors AMG 199 Metastatic GEJ cancer AMG 256 Solid tumors AMG 330 Acute myeloid leukemia AMG 340 Prostate cancer AMG 404 Solid tumors AMG 427 Acute myeloid leukemia AMG 506 Solid tumors AMG 509 Prostate cancer AMG 609 Nonalcoholic steatohepatitis AMG 650 Solid tumors AMG 994 Solid tumors 17 Phase\u00a03 Clinical trials investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study.",
      "score": -0.9842
    }
  ],
  "forward_snippets": [
    "A biotechnology pioneer, Amgen has grown to be one of the world\u2019s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.",
    "Products/Pipeline Inflammation Otezla \u2022 In December 2021, we announced that the FDA had approved the expanded indication for Otezla for the treatment of adult patients with plaque psoriasis, who are candidates for phototherapy or systemic therapy, across all severities.",
    "A biotechnology pioneer, Amgen has grown to be one of the world\u2019s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.",
    "Products/Pipeline Inflammation Otezla \u2022 In December 2021, we announced that the FDA had approved the expanded indication for Otezla for the treatment of adult patients with plaque psoriasis, who are candidates for phototherapy or systemic therapy, across all severities.",
    "We expect that both of these facilities will be built faster and at lower cost than traditional plants."
  ],
  "curated_text": "Symbol: AMGN. Year: 2022. Period: Y2022. ReportType: K10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: (a) (b) (c) Plan category Number of securities to be issued upon exercise of outstanding options and rights Weighted-average exercise price of outstanding options and rights Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) Equity compensation plans approved by Amgen security holders: Amended and Restated 2009 Equity Incentive Plan (1) 10,217,143 $ 197.27 18,987,053 Amended and Restated 1991 Equity Incentive Plan (2) 3,550 \u2014 \u2014 Amended and Restated Employee Stock Purchase Plan \u2014 \u2014 4,280,585 Total approved plans 10,220,693 197.27 23,267,638 Equity compensation plan not approved by Amgen security holders: Amgen Profit Sharing Plan for Employees in Ireland (3) \u2014 \u2014 242,172 Total unapproved plans \u2014 \u2014 242,172 Total all plans 10,220,693 $ 197.27 23,509,810 (1) The Amended and Restated 2009 Equity Incentive Plan employs a fungible share-counting formula for determining the number of shares available for issuance under the plan. (a) (b) (c) Plan category Number of securities to be issued upon exercise of outstanding options and rights Weighted-average exercise price of outstanding options and rights Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) Equity compensation plans approved by Amgen security holders: Amended and Restated 2009 Equity Incentive Plan (1) 10,217,143 $ 197.27 18,987,053 Amended and Restated 1991 Equity Incentive Plan (2) 3,550 \u2014 \u2014 Amended and Restated Employee Stock Purchase Plan \u2014 \u2014 4,280,585 Total approved plans 10,220,693 197.27 23,267,638 Equity compensation plan not approved by Amgen security holders: Amgen Profit Sharing Plan for Employees in Ireland (3) \u2014 \u2014 242,172 Total unapproved plans \u2014 \u2014 242,172 Total all plans 10,220,693 $ 197.27 23,509,810 (1) The Amended and Restated 2009 Equity Incentive Plan employs a fungible share-counting formula for determining the number of shares available for issuance under the plan. (a) (b) (c) Plan category Number of securities to be issued upon exercise of outstanding options and rights Weighted-average exercise price of outstanding options and rights Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) Equity compensation plans approved by Amgen security holders: Amended and Restated 2009 Equity Incentive Plan (1) 10,217,143 $ 197.27 18,987,053 Amended and Restated 1991 Equity Incentive Plan (2) 3,550 \u2014 \u2014 Amended and Restated Employee Stock Purchase Plan \u2014 \u2014 4,280,585 Total approved plans 10,220,693 197.27 23,267,638 Equity compensation plan not approved by Amgen security holders: Amgen Profit Sharing Plan for Employees in Ireland (3) \u2014 \u2014 242,172 Total unapproved plans \u2014 \u2014 242,172 Total all plans 10,220,693 $ 197.27 23,509,810 (1) The Amended and Restated 2009 Equity Incentive Plan employs a fungible share-counting formula for determining the number of shares available for issuance under the plan. Top negative sentences: 16 Molecule Investigational indication Phase 3 programs AMJEVITA Interchangeability Bemarituzumab GEJ adenocarcinoma BLINCYTO Ph-negative B-cell precursor Acute lymphoblastic leukemia EVENITY Male osteoporosis KYPROLIS Weekly dosing for relapsed multiple myeloma Nplate Chemotherapy-induced thrombocytopenia Otezla Genital psoriasis Repatha Cardiovascular disease TEZSPIRE Chronic rhinosinusitis with nasal polyps Severe asthma ABP 654 Investigational biosimilar to STELARA (ustekinumab) ABP 938 Investigational biosimilar to EYLEA (aflibercept) ABP 959 Investigational biosimilar to SOLIRIS (eculizumab) Phase 2 programs Efavaleukin alfa Systemic lupus erythematosus Ulcerative colitis LUMAKRAS/LUMYKRAS Advanced colorectal cancer NSCLC monotherapy Other solid tumors with KRAS G12C mutations Olpasiran Cardiovascular disease Ordesekimab Celiac disease Otezla Palmoplantar pustulosis Rozibafusp alfa Systemic lupus erythematosus Tarlatamab Small cell lung cancer TEZSPIRE Chronic obstructive pulmonary disease Chronic spontaneous urticaria AMG 451/KHK 4083 Atopic dermatitis Phase 1 programs Acapatamab Prostate cancer Pavurutamab Multiple myeloma Tarlatamab Small-cell lung cancer AMG 104 Asthma AMG 119 Small-cell lung cancer AMG 133 Obesity AMG 176 Hematologic malignancies AMG 193 Solid tumors AMG 199 Metastatic GEJ cancer AMG 256 Solid tumors AMG 330 Acute myeloid leukemia AMG 340 Prostate cancer AMG 404 Solid tumors AMG 427 Acute myeloid leukemia AMG 506 Solid tumors AMG 509 Prostate cancer AMG 609 Nonalcoholic steatohepatitis AMG 650 Solid tumors AMG 994 Solid tumors 17 Phase\u00a03 Clinical trials investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study. 16 Molecule Investigational indication Phase 3 programs AMJEVITA Interchangeability Bemarituzumab GEJ adenocarcinoma BLINCYTO Ph-negative B-cell precursor Acute lymphoblastic leukemia EVENITY Male osteoporosis KYPROLIS Weekly dosing for relapsed multiple myeloma Nplate Chemotherapy-induced thrombocytopenia Otezla Genital psoriasis Repatha Cardiovascular disease TEZSPIRE Chronic rhinosinusitis with nasal polyps Severe asthma ABP 654 Investigational biosimilar to STELARA (ustekinumab) ABP 938 Investigational biosimilar to EYLEA (aflibercept) ABP 959 Investigational biosimilar to SOLIRIS (eculizumab) Phase 2 programs Efavaleukin alfa Systemic lupus erythematosus Ulcerative colitis LUMAKRAS/LUMYKRAS Advanced colorectal cancer NSCLC monotherapy Other solid tumors with KRAS G12C mutations Olpasiran Cardiovascular disease Ordesekimab Celiac disease Otezla Palmoplantar pustulosis Rozibafusp alfa Systemic lupus erythematosus Tarlatamab Small cell lung cancer TEZSPIRE Chronic obstructive pulmonary disease Chronic spontaneous urticaria AMG 451/KHK 4083 Atopic dermatitis Phase 1 programs Acapatamab Prostate cancer Pavurutamab Multiple myeloma Tarlatamab Small-cell lung cancer AMG 104 Asthma AMG 119 Small-cell lung cancer AMG 133 Obesity AMG 176 Hematologic malignancies AMG 193 Solid tumors AMG 199 Metastatic GEJ cancer AMG 256 Solid tumors AMG 330 Acute myeloid leukemia AMG 340 Prostate cancer AMG 404 Solid tumors AMG 427 Acute myeloid leukemia AMG 506 Solid tumors AMG 509 Prostate cancer AMG 609 Nonalcoholic steatohepatitis AMG 650 Solid tumors AMG 994 Solid tumors 17 Phase\u00a03 Clinical trials investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study. 16 Molecule Investigational indication Phase 3 programs AMJEVITA Interchangeability Bemarituzumab GEJ adenocarcinoma BLINCYTO Ph-negative B-cell precursor Acute lymphoblastic leukemia EVENITY Male osteoporosis KYPROLIS Weekly dosing for relapsed multiple myeloma Nplate Chemotherapy-induced thrombocytopenia Otezla Genital psoriasis Repatha Cardiovascular disease TEZSPIRE Chronic rhinosinusitis with nasal polyps Severe asthma ABP 654 Investigational biosimilar to STELARA (ustekinumab) ABP 938 Investigational biosimilar to EYLEA (aflibercept) ABP 959 Investigational biosimilar to SOLIRIS (eculizumab) Phase 2 programs Efavaleukin alfa Systemic lupus erythematosus Ulcerative colitis LUMAKRAS/LUMYKRAS Advanced colorectal cancer NSCLC monotherapy Other solid tumors with KRAS G12C mutations Olpasiran Cardiovascular disease Ordesekimab Celiac disease Otezla Palmoplantar pustulosis Rozibafusp alfa Systemic lupus erythematosus Tarlatamab Small cell lung cancer TEZSPIRE Chronic obstructive pulmonary disease Chronic spontaneous urticaria AMG 451/KHK 4083 Atopic dermatitis Phase 1 programs Acapatamab Prostate cancer Pavurutamab Multiple myeloma Tarlatamab Small-cell lung cancer AMG 104 Asthma AMG 119 Small-cell lung cancer AMG 133 Obesity AMG 176 Hematologic malignancies AMG 193 Solid tumors AMG 199 Metastatic GEJ cancer AMG 256 Solid tumors AMG 330 Acute myeloid leukemia AMG 340 Prostate cancer AMG 404 Solid tumors AMG 427 Acute myeloid leukemia AMG 506 Solid tumors AMG 509 Prostate cancer AMG 609 Nonalcoholic steatohepatitis AMG 650 Solid tumors AMG 994 Solid tumors 17 Phase\u00a03 Clinical trials investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study. Forward-looking snippets: A biotechnology pioneer, Amgen has grown to be one of the world\u2019s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. Products/Pipeline Inflammation Otezla \u2022 In December 2021, we announced that the FDA had approved the expanded indication for Otezla for the treatment of adult patients with plaque psoriasis, who are candidates for phototherapy or systemic therapy, across all severities. A biotechnology pioneer, Amgen has grown to be one of the world\u2019s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. Products/Pipeline Inflammation Otezla \u2022 In December 2021, we announced that the FDA had approved the expanded indication for Otezla for the treatment of adult patients with plaque psoriasis, who are candidates for phototherapy or systemic therapy, across all severities. We expect that both of these facilities will be built faster and at lower cost than traditional plants."
}